VERU Veru Pharma: Bozor kapitallashuvining balans qiymatiga nisbati

Veru Pharma (VERU) - korporativ logo

Veru Inc. (VERU) yetakchi onkologlar va biologlarni raqobatbardosh kompensatsiya va o'z kashfiyotlarini amaliyotga tatbiq etish imkoniyatini taklif qilish orqali jalb qiladi. Biroq, biznesning muvaffaqiyati yangi dori sinovlari natijalariga va hozirda 1.39 ni tashkil etuvchi kuyish darajasiga juda bog'liq. Hozirgi narx harakati reproduktiv salomatlik mahsulotlaridan olinadigan foyda onkologiya terapiyasini ishlab chiqish bilan bog'liq moliyaviy xavflarni minimallashtiradigan muvozanatli yondashuvni aks ettiradi.

Veru Inc. (VERU) - Bozor kapitallashuvining balans qiymatiga nisbati 04.07.2022dan 28.10.2026gacha

VERU (Veru Inc): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari Veru Inc.|VERU - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor kapitallashuvi Veru Pharma|VERU - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya hisobiga balans qiymati Veru|VERU - Balans kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati verupharma.com|VERU - Biznesning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning kapitalga nisbati Veru Inc.|VERU - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati Veru Pharma|VERU - Kompaniyaning umumiy yig'indi qarzi|Qarzning balans kapitallashuviga nisbati Veru Pharma
Fundamental baholash:VERU (Veru Inc.)
Veru Inc tayyor mahsulotlari

Ushbu koeffitsiyent sof aktivlar qiymatidan yuqori bo'lgan bozor premiumini belgilab, investorlar kitob kapitalining har bir rubli uchun qancha qo'shimcha to'lov qilishga tayyorligini ko'rsatadi. Veru Inc. (VERU) uchun ushbu metrika intellektual mulkning kapitalizatsiyasi va saraton terapiyasi bo'yicha patent portfelini aks ettiradi. P/B koeffitsiyenti grafigini tahlil qilish orqali kompaniyaning monopol huquqlarining bozor baholash barqarorligini baholash mumkin. Yuqori multiplikator dori vositalarining kengayish imkoniyatlariga bozor ishonchini tasdiqlaydi. Biroq, kitob qiymatidan sezilarli farq klinik sinovlar muvaffaqiyatsiz tugashi holatida tebranishlar xavfini oshiradi.

Asosiy raqobatchilar

ONC: Kapitallashuvning sof aktivlarga nisbati|halozyme.com (HALO) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati RVMD|Kapitallashuvning sof aktivlarga nisbati Ascentage Pharma Group International|Bozor kapitallashuvining balans qiymatiga nisbati CGON|Bozor kapitallashuvining balans qiymatiga nisbati URGN (UroGen Pharma Corp)|BCAX - Bozor qiymatining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati personalis.com PSNL|ERAS: Bozor kapitallashuvining balans qiymatiga nisbati|DCTH - Kapitallashuvning sof aktivlarga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati YMAB|AURA (Aura Corp) - Bozor qiymatining balans qiymatiga koeffitsiyenti|CADL - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati accuray.com (ARAY)|SELLAS Life Sciences (SLS) - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati Actuate Therapeutics Inc. (ACTU)|Citius Oncology, Inc - Bozor kapitallashuvining balans qiymatiga nisbati|HURA - Kapitallashuvning sof aktivlarga nisbati|Protara Therapeutics - Kapitallashuvning sof aktivlarga nisbati|FATE: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati aadibio.com WHWK|TScan Therapeutics, Inc. (TCRX) - Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati CSBR (Champions Oncology Inc)|Bozor qiymatining balans qiymatiga koeffitsiyenti XBiotech USA (XBIT)|Kapitallashuvning sof aktivlarga nisbati CEL-SCI Corporation (CVM)|Bozor qiymatining balans qiymatiga nisbati ostherapies.com (OSTX)|RADX: Bozor kapitallashuvining balans qiymatiga nisbati|Artiva Biotherapeutics Inc. - Bozor qiymatining balans qiymatiga koeffitsiyenti|Bozor qiymatining balans qiymatiga nisbati Adlai Nortye Limited (ANL)|Tempest Therapeutics Corp (TPST) - Balans qiymatiga nisbatan bozor qiymati|XLO: Kapitallashuvning sof aktivlarga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati Renovaro|MURA - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati Kairos Pharma Inc|OKUR (OnKure Therapeutics Inc) - Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi GDTC (w2.cytomed.sg)|CRIS - Bozor qiymatining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati Apollomics Inc. APLM|THAR: Bozor kapitallashuvining balans qiymatiga nisbati|Advanced Biomed Inc (ADVB) - Kapitallashuvning sof aktivlarga nisbati|Genprex, Inc - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi Calidi Biotherapeutics, Inc.|Kapitallashuvning sof aktivlarga nisbati Sunshine Biopharma|Bozor qiymatining balans qiymatiga nisbati Xenetic Bio|Salarius Pharmaceuticals, Inc. - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti PPBT (Purple Biotech Ltd)|Bozor qiymatining balans qiymatiga nisbati American Oncology Network, Inc.|BGNE - Balans qiymatiga nisbatan bozor qiymati|Checkpoint Therapeutics - Kapitallashuvning sof aktivlarga nisbati|ELEV - Bozor kapitallashuvining balans qiymatiga nisbati|ICAD (icadmed.com) - Bozor kapitallashuvining balans qiymatiga nisbati|Ikena Oncology (IKNA) - Kapitallashuvning sof aktivlarga nisbati|NTBL (Notable Labs Inc.) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati VIRX|Bozor qiymatining balans qiymatiga nisbati MorphoSys AG MOR|Kapitallashuvning balans qiymatiga nisbati nayabiosciences.com (NAYA)|Ascentage Pharma - Bozor kapitallashuvining balans qiymatiga nisbati